Recombinant Human Endostatin Combined With Cisplatin For Malignant Pleural Effusion: A Clinical Study

Objective To evaluate the short-term curative efficacy and safety of recombinanthuman endostatin plus cisplatin(thoracic cavity perfusion)formalignant pleuraleffusion.Methods60cases of patients with malignant pleural effusion were randomly divided intotreatment group and control group. The control group was treated with DDP pleural perfusion, andthe treatment group was treated with DDP combined endostar by sequential pleural perfusion.1month after treat ment the clinical efficacy and toxicity were evaluated. Before and after therapyby pleural perfus ion the VEGF levels in pleural effusion detected by ELISA method.Results After therapy, the VEGF levels in pleural effusion were significantlydecreased, compared with prior-treatment the difference was significant (P<0.05), Allpatients completed the therapy of1cycles, the short-termclinical efficacy rate of thetreatment group was76.67%, the control group was43.8%, compared the differentwas significant (P<0.05).The adverse effect such as fever、nausea vomit andleukopenia ocurred in both group，but there no significant difference in two group.Conclusions DDP combined endostar by sequential pleural perfusion hasobvious curative effect, light toxicity. The program of therapy can inhibi t tumorgrowth and metastasis by inhibiting the expression of VEGF.